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Abstract
The cbf gene from Neisseria meningitidis strain MC58 encoding the putative Cell Binding
Factor (CBF, NMB0345/NEIS1825) protein was cloned into the pRSETA system and a ~36-
kDa recombinant (r)CBF protein expressed in Escherichia coli and purified by metal affinity
chromatography. High titres of rCBF antibodies were induced in mice following immuniza-
tion with rCBF-saline, rCBF-Al(OH)3, rCBF-Liposomes or rCBF-Zwittergent (Zw) 3–14
micelles, both with and without incorporated monophosphoryl lipid A (MPLA) adjuvant. Anti-
rCBF sera reacted in western blots of meningococcal lysates with a single protein band of
molecular mass ~29.5 kDa, indicative of mature CBF protein, but did not react with a lysate
of a Δnmb0345mutant (CBF-), demonstrating specificity of the murine immune responses.
CBF protein was produced by all strains of meningococci studied thus far and the protein
was present on the surface of MC58 (CBF+) bacteria, but absent on Δnmb0345mutant
(CBF-) bacteria, as judged by FACS reactivity of anti-rCBF sera. Analysis of the NEIS1825
amino acid sequences from 6644 N.meningitidis isolates with defined Alleles in the
pubmlst.org/Neisseria database showed that there were 141 ST types represented and
there were 136 different allelic loci encoding 49 non-redundant protein sequences. Only 6/
6644 (<0.1%) of N.meningitidis isolates lacked the nmb0345 gene. Amongst serogroup B
isolates worldwide, ~68% and ~20% expressed CBF encoded by Allele 1 and 18 respec-
tively, with the proteins sharing >99% amino acid identity. Murine antisera to rCBF in Zw
3–14 micelles + MPLA induced significant serum bactericidal activity (SBA) against homolo-
gous Allele 1 and heterologous Allele 18 strains, using both baby rabbit serum complement
and human serum complement (h)SBA assays, but did not kill strains expressing heterolo-
gous protein encoded by Alelle 2 or 3. Furthermore, variable bactericidal activity was
induced by murine antisera against different meningococcal strains in the hSBA assay,
which may correlate with variable surface exposure of CBF. Regardless, the attributes of
amino acid sequence conservation and protein expression amongst different strains and
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the ability to induce cross-strain bactericidal antibodies indicates that rCBF could be a
potential meningococcal vaccine antigen and merits further testing.
Introduction
Vaccination is the most effective prophylaxis for sepsis and meningitis caused by Neisseria
meningitidis (meningococcus). Capsular polysaccharide (CPS)-conjugate vaccines protect
against infections caused by serogroup A (MenA), C (MenC), Y (MenY) and W (MenW)
meningococci [1, 2], but this strategy is not effective for serogroup B (MenB) meningococcal
CPS [3]. Alternatively, sub-capsular MenB outer membrane (OM) vesicle vaccines have suc-
cessfully controlled clonal epidemics worldwide, but they provide no significant cross-strain
protection [4]. In silico reverse vaccinology and proteomic technologies have been used to
develop the Bexsero1 [5] and Trumenba1 [6–8] MenB vaccines, respectively. Bexsero1 was
licensed in 2013 by the European Medicines Agency for use in the European Union and recom-
mended for infant use in the UK [9, 10] and has been used also to control outbreaks of MenB
infection at two US universities [11]. Trumenba1 has been recommended for use in adoles-
cents [12, 13]. Strain coverage is a potential concern with these new MenB vaccines, with vary-
ing estimates for Bexsero1 in several European countries (73–89%), North America (66–88%),
Australia (76%) and Brazil (81%) [14–16]. A study of predictive coverage by Bexsero1 in the
Gipuzkoa region of Northern Spain during 2008–2013 estimated rates of 61.8% and 50%
respectively for MenB and non-MenB meningococci, which fell to 45% during 2012–2013 [17].
Protective bactericidal titers induced by Trumenba1 for toddlers and adolescents-young
adults, ranged from 44–100% and from 68–98%, respectively, against MenB strains expressing
heterologous vaccine proteins [7].
The meningococcal OM contains a large number of potential surface-exposed protein vac-
cine candidates. Immuno-proteomic study of serum obtained before and after colonisation or
infection with meningococci [18] demonstrated that increased reactivity with specific OM
proteins correlated with increased serum bactericidal activity (SBA), the generally accepted
correlate of protection in humans [19]. One of these proteins was a putative Cell Binding Fac-
tor (CBF; NMB0345 in MenB strain MC58; NMA2142 in MenA strain Z4970; NEIS1825,
pubmlst.org/Neisseria). CBF has homology to a major antigenic protein from Campylobacter
jejuni, Cj0596 (PEB4, Cell Binding Factor 2, CBF2), which has been shown to be important for
bacterial adherence to murine INT407 cells, for colonization of mouse intestinal epithelium
and for biofilm formation [20]. Using an infant rat model of meningococcal infection, Sun
et al. [21] identified NMB0345/CBF as one of 73 genes of MenB strain C311+ essential for
meningococcal septicaemia. NMB0345 has been reported to contribute towards meningococcal
adherence to epithelial cells [22] and potentially to colonization [23]. The nmb0345 gene was
also up-regulated in the presence of human haemoglobin [24] and was implicated in survival
in human blood [22]. To our knowledge, the vaccine potential of CBF has not been reported
and in the current study we provide evidence that CBF is a highly conserved, expressed and
surface accessible protein capable of inducing bactericidal antibodies.
Materials and Methods
Bacteria, growth conditions and preparation of OM
Neisseria meningitidis strain MC58 (B: 15:P1.7,16b) and 12 other meningococcal strains of dif-
ferent CPS serogroups, PorB protein serotypes, and PorA protein serosubtypes, originally
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isolated from patients orhh colonized individuals, have been described previously [18, 25]. N.
meningitidis strains M15 240010 (W: P1.5,2: F1-1: ST-11 (cc11)), M15 240190 (Y: P1.5,2: F5-
58: ST-11 (cc11)), M15 240016 (B: P1.12–1,16: F1-5: ST-485 (cc41/44)), M15 240120 (B:
P1.22,14: F3-6: ST-2100 (cc213)) and M15 240106 (B: P1.7–1,1: F1-5: ST-41 (cc41/44)) were
obtained from the Public Health England Meningococcal Reference Unit, Manchester. MC58
Δnmb0345mutant strain was obtained from K. Wooldridge, University of Nottingham.
Meningococci were grown on supplemented GC agar plates incubated at 37°C with an atmo-
sphere of 5% (vol/vol) CO2 [18]. E. coliDH5α (cloning) and BL21(DE3) pLysS (protein expres-
sion) strains (Invitrogen, UK) were grown on Luria-Bertani (LB) agar, LB broth or SOB with
or without addition of selective antibiotics. Whole meningococcal suspensions were prepared
in water and OM was prepared by extraction of whole bacteria with 0.2 M lithium acetate
buffer, pH 5.8 [26] and differential ultracentrifugation [27].
Cloning and expression of the cbf gene in E. coli
Genomic DNA of MC58 was extracted by alkaline lysis [25] and used as the PCR template.
The cbf gene sequence encoding the entire coding sequence for the NMB0345 protein (867 bp,
NCBI), including the signal leader peptide and the following lipidation site (Cys21) was ampli-
fied using forward primer NMB0345F (5’-ggctatctcgagatgaaagcaaaaatcctgac-
3’), reverse primer NMB0345R (5’-ggctataagcttctattattttgcaggtttgatgt
-3’) and 2× Phusion PCR master mix (ThermoScientific, UK) under the following PCR con-
ditions: initial denaturation (98°C, 30 s), 30 cycles of denaturation (98°C, 10 s), annealing
(57°C, 30 s) and extension (72°C, 26 s) and a final extension (72°C for 5 min). The restriction
site sequences for XhoI and HindIII enzymes are ctcgag and aagctt, respectively. The method
for gene cloning into the pRSETA system with an N-terminus HIS-tag was described previ-
ously [25]. Recombinant plasmids carrying the cbf gene, which was confirmed by sequence
analysis, were transformed into E. coli BL21(DE3) pLysS and protein expression was induced
by addition of isopropyl-β-d-thiogalactopyranoside (1 mM final concentration), followed by
bacterial growth for 4 h.
Purification of rCBF
rCBF protein was purified using nickel-nitrilotriacetic acid metal-affinity chromatography
under denaturing conditions (QIAexpressionist; Qiagen, UK). Bound protein was eluted with
100 mMNaH2PO4 buffer, 10 mM Tris, 8 M urea buffer, pH 4.5. Samples obtained during puri-
fication were analyzed using 12% (wt/vol) SDS-PAGE electrophoresis (Mini-protean system,
Bio-Rad, UK), then pooled and precipitated using 100% (vol/vol) ethanol overnight. The pro-
tein pellet was solubilised in phosphate buffered saline (PBS, pH7.4) containing 0.5% (wt/vol)
sodium dodecyl sulphate (SDS) and the protein concentration was determined using the
bicinchoninic acid assay (ThermoScientific, UK). Purity of rCBF protein was assessed by
SDS-PAGE and western blot reactivity with rabbit anti-rCBF antiserum (1/400 dilution) and
mouse anti-HIS tag antibody (Invitrogen 372900, 1/500).
Sequencing the cbf gene
The cbf gene of selected meningococcal strains was sequenced commercially (Source BioSci-
ence, Oxford, UK) using primers s0345F (5’-gtcaaatcgctgctcaaaga-3’) and s0345R
(5’- caccagcgtatccaccaaag-3’). Additional meningococcal cbf gene (NEIS1825)
sequences were obtained from http://pubmlst.org/neisseria/ and sequence alignments gener-
ated using Clustal (http://www.ebi.ac.uk/Tools/msa/clustalo/) and a dendrogram assembled
with Jalview 2.8 (www.jalview.org).
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Immunization of animals
BALB/c mice (H-2d haplotype) and New Zealand White (NZW) rabbits were housed under
standard conditions of temperature and humidity with a 12h lighting cycle and with food and
water available ad libitum. BALB/c mice were bred within the animal facilities of the university
and NZW rabbits were purchased from Harlan, UK (now Envigo). Groups of five male BALB/
c mice of approximate equal sizes and weights (6–7 weeks of age) were immunized intraperito-
neally with rCBF-saline, rCBF-Al(OH)3, rCBF-liposomes ± MPLA, and rCBF-Zwittergent
(Zw) 3–14 micelles ± MPLA formulations, prepared using methods described previously [25].
For immunization, the stock protein, solubilized in 0.5% (wt/vol) SDS in PBS was diluted in
saline for the preparation of working stocks. The immunization schedule was rCBF (20 μg/
mouse) on days 0, 14, and 28. Groups of five mice were also sham-injected with the same for-
mulations without rCBF and one group was kept for normal serum. Generation of murine anti-
sera to MC58 OM has been described previously [25]. Mice were terminally bled by cardiac
puncture under anesthesia on day 42.
Female NZW rabbits (n = 2) were immunized subcutaneously with rCBF (50 μg/dose)
emulsified in Freund’s complete adjuvant (dose I) and Freund’s incomplete adjuvant (doses
II-IV) at 14-day intervals. Rabbits were terminally bled from the middle ear vein followed by
cardiac puncture under anesthesia, 14 days after the last dose. All sera were stored at −20°C
until required. This study complied with the animal experimentation guidelines of the Home
Office, with approval granted under the Animals (Scientific Procedures) Act, 1986) and was
approved by the Animal Welfare and Ethics Review Board (AWERB) at the authors’ institution
(University of Southampton). Animal health and welfare was assessed daily by qualified animal
technicians and no animals suffered significant adverse effects.
Characterization of biological and functional properties of antibodies to
rCBF
Enzyme-linked immunosorbent assay (ELISA). Individual sera were reacted with rCBF
and homologous OM in ELISA, as described previously [28]. Sera were also reacted against
whole MC58 meningococcal cells: briefly, from an overnight agar plate culture of meningo-
cocci, bacterial growth was suspended in PBS and the concentration in colony forming units
(CFU) was determined by viable counting. ELISA wells were coated with 100μl of carbonate
coating buffer, pH9.6 containing 1×107 CFU and subsequent steps for the whole bacterial cell
ELISA were identical to the rCBF and OM ELISA. Absorbance was measured at λ450 nm after
10 min of incubation with enzyme substrate, and the ELISA titer, extrapolated from the linear
portion of the serum titration curve, was taken as the reciprocal dilution which gave an increase
in absorbance of 0.1 U after 10 min. An independent t-Test was used to compare differences
between mean values for ELISA data, with p values<0.05 considered significant.
SDS-PAGE and western immunoblotting. OM or whole-cell lysate preparations (10 μg/
lane) were separated on SDS-PAGE, transferred to nitrocellulose using semi-dry blotting and
immunological reactivity detected as described previously [28].
Fluorescence-activated cell sorter (FACS) analysis. Methods for sample preparation,
antibody binding to whole bacteria, detection with FITC-conjugated species-specific IgG
reagents and analyses on a FACSAria flow cytometer (BD Biosciences), have all been described
previously [29]. A one sample t-Test was used to compare the mean fluorescence values for
antisera raised to rCBF and corresponding sham-immunized sera when tested against parent
MC58 (CBF+) bacteria and the MC58Δnmb0345 (CBF-) knock-out strain, with p values<0.05
considered significant. A one-sample t-Test was also used to compare the mean fluorescence
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values for rabbit antiserum to rCBF and the corresponding pre-immune serum, tested against
MC58 wild-type and knock-out strains.
Complement-activated killing of meningococci. The bactericidal activities of pooled
antisera were determined with 5% (v/v) baby rabbit serum complement (BRC) (AbD Serotec,
UK) and 25% (v/v) Ig-depleted human serum complement (HC) as described previously [28,
30]. Quality control of human complement source was determined as described previously
[30]. Complement-dependent bactericidal activity was determined from the numbers of bacte-
ria surviving in the presence of serum and complement compared to the numbers surviving
with complement but without test serum. Sera that showed bactericidal activity (>50%) in two
or more dilutions were considered positive and statistical significance was accepted with p val-
ues<0.05 as determined with a two-sample t-Test, comparing the CFU survivors in the pres-
ence of serum and complement with the CFU survivors in the presence of complement alone
(no serum).
Results
Bioinformatic analysis
Full-length CBF (NMB0345) is a protein of 288 amino acids and is predicted to be a lipoprotein
with a cleavage site between amino acids 20–21, mediated by type I signal peptidase (http://
www.cbs.dtu.dk/services/LipoP/) (Fig 1A). Full-length CBF has a predicted molecular mass
(Mr) of 31455 daltons and an average isoelectric point (IP) of 9.636, whilst the mature protein
has a predictedMr of 29448 daltons and an average IP of 9.555 (Kozlowski LP. 2007–2013 Iso-
electric Point Calculator. http://isoelectric.ovh.org). Using the ProtParam tool (http://web.
expasy.org/protparam/), estimation of CBF hydropathy (as a Grand Average Hydropathy
(GRAVY) score) from the amino acid sequence was -0.436, with 36 negatively charged residues
(Asp, Glu) and 44 positively charged residues (Arg, Lys). The negative score denoted greater
hydrophilicity of the protein. Although PSORTb (version 3.0.2. http://www.psort.org/psortb/)
could not predict protein location (unknown), the fact that CBF is a lipoprotein with a cleav-
able signal peptide suggest that it is membrane localized. Initially, we used BLAST protein
amino acid sequence analysis (NCBI) to investigate the presence of CBF homologues within
meningococci, Neisseria gonorrhoeae and other bacteria. We identified the presence of a puta-
tive conserved PPIC-type peptidyl prolyl cis/trans isomerase (PPIase) domain (interval
133–259) belonging to the Rotamase_2 superfamily (Fig 1A and 1B). From BLAST analysis,
NMB0345 shares 25.3% identity (= 73/288 amino acids) with the C. jejuni PEB3/CBF2 protein
(273 amino acids,Mr 30.5kDa). NMB0345 can be putatively modelled in SWISS-model using
as a template the crystallized structure of 3rfw.1. A protein (PEB4), which is the most closely
related structure to C. jejuni PEB3/CBF2 that we have available in Protein Data Bank (Fig 1B).
The model predicts a globular domain that contains the putative conserved PPIC-type PPIase
domain (Val133-Lys259) extending from a ‘stalk’ of α-helices.
Cloning, expression and purification of rCBF
Expression of rCBF protein from the pRSETA-cbf vector transformed into E.coli BL21(DE3)
pLysS was induced with isopropyl-β-d-thiogalactopyranoside and E. coli bacteria were col-
lected by centrifugation and lysed. The lysate was centrifuged to produce a supernatant and
cell pellet and SDS-PAGE analysis demonstrated the presence of rCBF protein predominantly
in the insoluble fraction, necessitating purification under denaturing conditions. SDS-PAGE
analysis (Fig 2A) revealed a single band ofMr ~36 kDa, corresponding to full-length CBF
protein with an N-terminal sequence of 39 additional amino acids including the 6×HIS tag.
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Fig 1. A. Amino acid sequence alignment of NMB0345 (NEIS1825, Cell Binding Factor, CBF) fromN.meningitidis
MC58,N.gonorrhoeae FA1090 and theCampylobacter jejuni PEB3/CBF2 protein. * denotes identical amino acids
between all three proteins. Yellow-shaded amino acid sequences denote the putative signal leader peptides. The blue-
shaded amino acid sequence denotes the presence of a putative conserved PPIC-type peptidyl prolyl cis/trans isomerase
domain (interval 133–259) belonging to the Rotamase_2 superfamily. B) Putative structure of meningococcal CBF based
Vaccine Potential and Diversity of the Meningococcal Putative Cell Binding Factor
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Recombinant protein reacted specifically in immunoblot with anti-HIS tag antibody and rabbit
anti-rCBF sera (Fig 2B and 2C) as a single band ofMr ~36 kDa.
rCBF protein induces humoral antibody responses in animals
ELISA of murine antisera raised against rCBF demonstrated that high (mean reciprocal
ELISA) titres of antibodies were induced by immunisation with rCBF-saline (~88,000) and
rCBF-liposomes (~30,000) (Fig 3A). Statistically higher (p<0.05) titres were induced by rCBF-
Al(OH)3 (~934,000) or rCBF-Zw 3–14 micelles (~430,000) compared to the latter. Addition of
MPLA into rCBF-liposomes and Zw 3–14 micelle preparations significantly increased serum
antibody titres, with mean reciprocal ELISA titres ~1.5–2 × 106 (p<0.05). Immunisation with
MC58 OM adsorbed to Al(OH)3 induced lower levels of antibodies (mean titre ~6,000) that
reacted with purified rCBF protein (Fig 3A).
onC.jejuniCBF. The structure of meningococcal CBF was putatively modelled in SWISS-model, using as a template the
crystallized structure of 3rfw.1.A protein (PEB4), which is the most closely related structure to C. jejuni PEB3/CBF2 that we
have available in Protein Data Bank.
doi:10.1371/journal.pone.0160403.g001
Fig 2. Purification of recombinant (r)CBF. The protein was purified to homogeneity using nickel-nitrilotriacetic acid metal affinity
chromatography under denaturing conditions. A) SDS-PAGE analysis of purified rCBF. Lane 1, molecular mass markers; lane 2,
rCBF (2 μg) showing a single band of ~36 kDa.B) Western blot analysis of purified rCBF reacted with anti-HIS tag antibody.
Lane 1, molecular mass markers. Lane 2, protein reactivity with anti-HIS antibody (1/500) showing a single band of ~36 kDa.C)
Western blot analysis of purified rCBF reacted with rabbit polyclonal anti-rCBF serum. Lane 1, molecular mass markers. Lane
2, protein reactivity with rabbit anti-rCBF serum (1/400) showing a single band of ~36 kDa.
doi:10.1371/journal.pone.0160403.g002
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The murine anti-rCBF antisera were also tested in ELISA against MC58 OM (Fig 3B) and
whole meningococcal cells (Fig 3C). Weak reactivity with both preparations was observed with
antisera raised to rCBF in saline, Al(OH)3 and in liposomes and Zw 3–14 micelles, both with
MPLA. In general, mean reciprocal ELISA titres were significant (p<0.05) but low (ranging
Fig 3. ELISA reactivity of antisera raised to different rCBF formulations against pure rCBF protein,
outer membranes (OM) and whole meningococcal cells. Antisera from individual animals immunized with
rCBF in various adjuvant and delivery formulations and from animals immunised with OM, were reacted in
ELISA againstA) purified rCBF protein, B) MC58 OM and C) whole MC58meningococcal cells. The
columns represent the geometric mean reciprocal ELISA titres (n = 4 or 5 animals per group) and the error
bars represent the 95% confidence limits. No significant reactivity with rCBF, OM or whole cells in ELISA was
observed with sera from sham-immunized animals or with normal mouse serum (absorbance values λ450nm
<0.1 for serum dilutions of 1/10). The * denotes that the responses were statistically higher than the
corresponding sham-immunized animals (p<0.05), using an independent t-Test to compare differences
between the mean values.
doi:10.1371/journal.pone.0160403.g003
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from ~1500–7000) and with variability in the responses of individual animals within each
group. No reactivity was observed with antisera raised to rCBF in liposomes or Zw 3–14
micelles alone (Fig 3B and 3C). As expected, the reactivity of murine anti-OM sera against
both MC58 OM and whole bacterial cells in ELISA was significantly higher than any of the
murine antisera (p<0.05), with mean reciprocal ELISA titres of ~230,000 (Fig 3B) and
~100,000 (Fig 3C), respectively. Rabbit antisera raised to MC58 rCBF in Freund’s adjuvants
was also tested in ELISA. Pre-immune rabbit serum did not react with purified rCBF (λ450nm
absorbance values<0.1 for serum dilutions of 1/10) whereas post-immune rabbit serum dem-
onstrated reciprocal ELISA titres ~130,000 against the protein. In addition, pre-immune rabbit
serum showed no significant reactivity with both MC58 OM and whole bacterial cells in ELISA
(titre<1000), whereas post-immune rabbit anti-rCBF serum reacted with OM and whole bac-
terial cells with reciprocal ELISA titres of 128,000 and 112,000 respectively. The hyper-reactiv-
ity of rabbit antiserum is likely a reflection of the potency of the Freund’s adjuvant and the
dose and immunization schedule used for rCBF antigen in rabbits.
Western immuno-blotting demonstrated specificity of the murine immune responses (Fig
4A): antisera to rCBF-saline, rCBF-Al(OH)3, rCBF-liposomes ± MPLA and rCBF-Zw 3–14
micelles ± MPLA reacted with a single protein band ofMr ~29.5 kDa, which is consistent with
homologous CBF protein in MC58 OM, whereas sera from sham-immunised mice were non-
reactive. Specificity was confirmed by the lack of reactivity of murine antisera with the MC58
Δnmb0345 knock-out strain that does not express CBF protein in the OM (Fig 4A). Murine
antisera raised to MC58 OM adsorbed to Al(OH)3 was also tested in western blot against
MC58Wt and MC58 Δnmb0345 knock-out strains as shown in S1 Fig: as expected, the position
of the CBF band cannot be resolved from the complex multiple protein reactivity patterns for
both preparations.
Antibodies recognise CBF on MC58 meningococci
Antisera to rCBF in the various formulations reacted with MC58 (CBF+) bacteria, showing sig-
nificant (p<0.05) and right-shifted increases in FITC-fluorescence recorded events, compared
to sham-immunised murine sera (Fig 4B). Post-immune rabbit antiserum also showed signifi-
cant (p<0.05) and right-shifted increase in FITC fluorescence-recorded events, compared to
pre-immune serum. Specificity was confirmed by the lack of reactivity (P>0.05) of all murine
antisera and rabbit post-immune serum with the MC58 Δnmb0345 knock-out (CBF-) strain
(Fig 4B).
In the western blot of antisera raised to rCBF-Zw 3–14 micelles + MPLA tested against the
wild-type MC58, reactivity was also observed against a second minor band ofMr ~25kDa (Fig
4A), which was lower than the reactivity of this antiserum pool against the CBF protein
(~29kDa). In addition, a second flow cytometry peak was observed when this antiserum pool
was reacted against wild-type MC58, but not against the knock-out strain (Fig 4B). This cross-
reactivity was not due to contamination of the rCBF used for immunization (Fig 2), since anti-
sera raised to rCBF with any of the other preparations did not demonstrate a similar minor
band (Fig 4A). This secondary minor band likely represents some murine antibody cross-reac-
tivity with MC58, but it does not contribute to bactericidal activity, since no killing of the
MC58Δnmb0345 strain was observed with the bactericidal antisera raised to rCBF-Zw 3–14
micelles + MPLA (Table 1 below) using the baby rabbit complement serum bactericidal assay.
CBF is highly conserved and expressed in meningococci
The DNA sequences of the cbf gene (NEIS1825) from N.meningitidis isolates in the pubmlst.
org/Neisseria database [31]—which contains data for an increasing collection of isolates
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Fig 4. A) Specificity of murine anti-rCBF sera, examined by western immunoblot reactivity with CBF
protein present in MC58 lysates. Pooled antisera (1/100 dilution) were reacted against wild-type MC58
lysate (Wt) and MC58 Δnmb0345 knock-out lysate (Δ) in western blot. CBF was recognised as a single
protein band ofMr ~29.5 kDa (identified by the arrow) in wild-type MC58 (CBF+) but not in the knock-out
strain (CBF-). All sham immunization sera and normal mouse serum were non-reactive against both Wt and
knock-out strains, as demonstrated by representative strip blots (control*). B) CBF is expressed on the
surface of MC58meningococci as demonstrated by FACS analysis. On the top panel, the area within the
red lines show no reactivity of wild-type MC58 (CBF+) bacteria with murine sham-immunised serum (1/10)
and the area within the blue lines shows the significant FACS reactivity of murine antisera (1/10) raised
against rCBF in the various formulations. The lower panel shows corresponding reactivity of the same murine
sham-immunised sera and antisera against the MC58 Δnmb0345 (CBF-) knock-out strain. Rabbit post-
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representing the total known diversity of Neisseria species—were translated to amino acid
sequences and aligned. In a combined total of 6644 N.meningitidis strains in the database with
defined alleles, there are 141 Sequence Types (ST) represented. Using genome comparator,
only 6/6644 (<0.1%) of meningococcal isolates lacked the nmb0345 gene (id: 21459, 37778,
40426 (NG, non-groupable); 26977 (ND, not determined); 36468 (MenC); 40270 (MenW)),
although it is possible that their absence may reflect errors in gene sequencing. There were 136
different allelic loci for which isolates were identified, and analysis of the translated proteins
encoded by the nucleotide sequences of these different alleles identified 49 non-redundant
NMB0345 amino acid sequences (S2 and S3 Figs, S1 Table). Expression of four different CBF
proteins provided ~98% coverage of N.meningitidis isolates worldwide: the majority of menin-
gococci expressed a representative protein encoded by Allele 1 (75% (4976/6644) of isolates)
and this protein was found in MenA, MenB, MenC, MenE, MenH, MenW, MenX, MenY and
MenZ isolates (S1 Table). N.meningitidis also expressed representative CBF proteins encoded
by Alleles 18 (9%, 588/8844 isolates), 3 (9%, 599/6644 isolates) and 2 (5%, 303/6644 isolates)
and these were found mainly in MenB and MenC isolates (S1 Table). In MenB isolates specifi-
cally, 23 CBF proteins with different amino acid sequences were found, with the remaining
proteins expressed principally by MenY isolates with the occasional MenA, MenC, MenW and
MenZ isolate (S1 Table). There were 2692 MenB isolates (41% of all meningococci) and 99% of
immune serum (1/100) also reacted with the wild-type MC58 (CBF+) (area within the blue line), compared to
pre-immune serum (area within the red lines) and no reactivity was observed with the MC58 Δnmb0345
(CBF-) knock-out strain. The numbers within each panel refer to the FITC-mean value. The * denotes the
significant (p<0.05) and right-shifted increases in FITC-fluorescence recorded events, using a one sample t-
Test to compare mean fluorescence values of test murine antisera against sham-immunised murine sera or
rabbit post-immune antiserum against pre-immune serum. Data are representative of n = 2 experiments.
doi:10.1371/journal.pone.0160403.g004
Table 1. Serum bactericidal activity of murine anti-rCBF sera.
SBA titre induced by rCBF in ZW 3–14 + MPLA
Strain Serogroup NMB0345 Allele Baby rabbit complement Human complement
MC58 B 1 256 (128, 256) <4
MC168 B 1 1024 256
MC90 B 1 - 64
MC54 B 1 - <8
M15 240010 W 1 - 8
M15 240190 Y 1 - <8
L2470 B 18 256 (128, 256) 16
M15 240016 B 18 - <8
MC162 C 3 <4 -
MENC11 C 3 <4 -
M15 240120 B 2 - <8
M15 240106 B 2 - <8
Bactericidal activity was determined with both baby rabbit serum and human Ig-depleted serum as exogenous complement sources. Titres for antisera
raised to rCBF-saline, rCBF-Al(OH)3, rCBF-liposomes with and without MPLA, and rCBF-Zwittergent (Zw) 3–14 micelles alone as well as normal mouse
serum and sera from sham immunized mice using either baby rabbit (BRC) or human complement (HC) sources, where tested, were not bactericidal (<4
against MC58). In addition, anti-rCBF in ZW 3–14 + MPLA sera did not kill the MC58 Δnmb0345 knock-out strain (titre <4 using BRC). Data are the median
values, with the range of values in parenthesis, from two-three independent measurements of bactericidal activity of all pooled serum samples. Single values
denote that the bactericidal titres were identical from independent experiments.
- denotes not done for strains with BRC or HC, where no killing was observed with either assay.
doi:10.1371/journal.pone.0160403.t001
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these isolates were covered by CBF proteins representative of four Alleles: ~68% expressed rep-
resentative protein encoded by Allele 1 (1833 isolates), 20% by Allele 18 (541 isolates), 8% by
Allele 2 (213 isolates) and 3% by Allele 3 (72 isolates).
Examination of UK data collated during 2013–2015 for N.meningitidis strains in the data-
base showed that there were 1537 isolates recorded (S2 Table). The majority of N.meningitidis
isolates (90%) expressed representative CBF protein encoded by Allele 1 (79%, 1212/1537 iso-
lates), which was found broadly expressed by MenB, MenC, MenW and MenY isolates, fol-
lowed by Allele 18-encoded protein (11%, 164/1537 isolates), which was principally expressed
by MenB strains. There were 794 MenB isolates recorded (52% of all meningococci), with the
majority expressing a representative CBF protein encoded by Allele 1 (70%, 554/794 isolates)
or Allele 18 (20%, 158/794 isolates,).
To investigate CBF protein production amongst different meningococcal strains, bacterial
lysates from the 13 isolates from colonized individuals and from patients collected during an
outbreak of meningococcal disease [18, 25] were reacted with rabbit anti-rCBF serum in west-
ern blots. Translation of the nmb0345 gene sequences for these 13 isolates showed that they
expressed protein sequences encoded by Allele 1(MC58, MC54, MC90, MC161, MC168,
MC172, MC173, MC174, MC179, MC180), Allele 18 (L2470) or Allele 3 (MC162, MENC11).
Examination of the amino acid sequences for these three CBF proteins showed high conserva-
tion, with only 2 amino acid differences observed; Val138 (Alleles 1, 3) to Ile138 (Allele 18) and
Lys176 (Allele 1, 18) to Arg176 (Allele 3) (S2 Fig). Anti-rCBF sera reacted with a ~29.5kDa band
present in all isolates (Fig 5A). The band intensities were also quantified from the blots using
ImageJ software and appeared to be essentially similar (Fig 5B), with calculated mean ratios rel-
ative to MC58 between 1–2 (p>0.05).
Bactericidal activity of anti-rCBF sera
Initially, murine antisera were tested for their ability to promote killing of meningococcal strain
MC58 (encoding protein representative of Allele 1) in the presence of baby rabbit complement
(BRC, 5% v/v) (Table 1). Only sera raised against rCBF-Zw 3–14 micelles + MPLA showed sig-
nificant bactericidal activity against MC58 (reciprocal median titre 256 (64, 256), p<0.05) and
similar cross-strain bactericidal activity (reciprocal median titres of 256 (128, 512)) against
L2470, which expresses CBF encoded by Allele 18. To demonstrate specificity, rCBF-Zw 3–14
micelles + MPLA antisera did not kill the MC58 Δnmb0345 knock-out strain (titres<4) in the
presence of BRC. Sera from sham immunized animals and normal mouse serum did not induce
bactericidal activity (<4).
Bactericidal activity of rCBF-Zw 3–14 micelles + MPLA antiserum pool was then examined
using Ig-depleted human serum as a complement source (HC) in the more stringent hSBA
assay (25% v/v) (Table 1). However, no killing was observed against homologous strain MC58
(titre<4). Therefore, we tested this antiserum pool in the hSBA against other strains that
express protein encoded by Alelle 1: strains MC168 (MenB), MC90 (MenB) and M15 240010
(MenW) were killed by this antiserum pool (median titres of 256, 64 and 8 respectively), but
not strains MC54 (MenB) or M15 240190 (MenY) (Table 1). For strains expressing heterolo-
gous protein encoded by Allele 18, this antiserum pool killed strain L2470 (MenB) in the hSBA
with median titre 16, but not strain M15 240016 (MenB). No bactericidal activity (<4) was
observed for strains MC162 and MENC11 (both MenC strains), expressing heterologous CBF
encoded by Allele 3 with BRC, so these were not tested with HC (Table 1). We also tested this
antiserum pool against two MenB strains expressing protein encoded by Allele 2 (M15 240120
and M15 240106) but no bactericidal activity was observed with HC (Table 1).
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Fig 5. Production of CBF in different meningococcal strains examined by western blotting. A)Western blot reactivity of rabbit anti-rCBF
sera (1/100 dilution) with CBF in lysates (10 μg of total protein) of meningococcal strains MC58, MC54, MC90, MC161, MC168, MC172, MC173,
MC174, MC179 and MC180 (CBF encoded by Allele 1); L2470 (protein encoded by Allele 18) and MC162 and MENC11 (protein encoded by Allele
3). The blot is representative of n = 4 independent western blot experiments. B) For each of the blots, band intensities were quantified by ImageJ
and a mean value for each meningococcal strain was calculated with standard deviation (for the bands from the n = 4 independent blots) shown by
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Discussion
To our knowledge, this study is the first to demonstrate that a recombinant putative Cell Bind-
ing Factor protein (CBF, NMB0345/NEIS1825) can induce murine antibodies with bactericidal
activity against meningococci. The protein has been reported in several meningococcal OM/
OMV proteomes [26, 33–35] and despite PSORTb (3.0) failing to assign CBF to a bacterial
compartment, we provide evidence that the protein appears to be surface-accessible on MC58
bacteria. CBF belongs to the meningococcal immuno-OM proteome as reported in our initial
study [18], and in our current study, we demonstrated the reactivity of murine and rabbit anti-
rCBF sera with OM and whole meningococcal cells. The demonstrable bactericidal activity of
anti-rCBF sera for wild-type meningococci but not for a CBF knock-out strain suggests that
CBF is accessible on the surface of the bacterium to binding antibodies. This is confirmed by
the FACS reactivity of anti-rCBF sera with wild-type MC58 but not mutant meningococci:
indeed, FACS has been often used as an indicator of surface-accessibility of bactericidal anti-
bodies and as a selection tool for candidate Neisseria vaccine antigens identified by in silico
reverse vaccinology [5, 36].
We were also able to generate a putative model of the CBF protein based on the most closely
related C. jejuni PEB3/CBF2, using the PEB4 homologue as a template. The C. jejuni homo-
logue is a putative periplasmic protein, but examination of the amino acid sequences showed
that the meningococcal CBF protein shares only 73/288 amino acids with PEB3/CBF2 protein,
and that this similarity is evenly spread across the protein sequences. Moreover, the meningo-
coccal CBF protein has a globular domain, which contains the putative conserved PPIC-type
PPIase domain, which is similar in structure to the globular domains found in the Macrophage
Infectivity Potentiator (MIP)-like PPIase proteins that are expressed in the OM of the Neisser-
iae and other pathogens [37]. It is possible that meningococcal CBF does not function as a peri-
plasmic chaperone like the predicted function for C. jejuni PEB3/CBF2, but rather is an OM-
located, surface-exposed molecule with PPIase function like the MIP proteins. Taken together,
the observations that the meningococcal CBF shows only ~25% identity with the periplasmic
PEB3/CBF2 protein, has structural similarity to NeisseriaMIP protein(s), is a putative lipopro-
tein with a cleavable leader peptide and is capable of binding bactericidal antibodies, suggests
that the CBF protein is probably OM-located and surface-accessible.
Interrogation of NMB0345/NEIS1825 amino acid sequences from isolates reported in the
pubmlst.org/Neisseria database and our own strain collection demonstrated conservation of
this protein across meningococci. We demonstrated using western blot reactivity with rabbit
anti-rCBF serum that CBF was also produced by all strains examined thus far. rCBF could
induce functional bactericidal antibodies, but only when delivered in detergent micelles con-
taining exogenous MPLA adjuvant and surprisingly, not with several other adjuvants that are
compatible for human immunisation. The lack of bactericidal activity induced by rCBF with
these adjuvants did not correlate with the observations of production of high levels of specific
antibodies that reacted with surface-exposed CBF on meningococci and may reflect differences
in adjuvant-directed antigen processing and antibody avidity.
In the current study, we used initially the BRC SBA assay to examine bactericidal activity
and then tested the antisera in the more stringent human (h)SBA assay. The limitation of our
study was that finite serum volumes with repeated experiments to demonstrate reproducibility,
allowed only for a restricted number of strains expressing CBF proteins encoded by different
the error lines, as described previously [32]. For each blot, a ratio of band intensity relative to MC58 was also calculated for each strain and the
mean ratio values with standard deviations (n = 4) are tabulated and compared with a student’s t-Test (p values >0.05 for all strains relative to
MC58).
doi:10.1371/journal.pone.0160403.g005
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alleles to be tested in the SBA assays. Using the BRC SBA assay, we demonstrated initially that
anti-rCBF sera raised in Zw 3–14 micelles with MPLA killed the homologous strain MC58
(CBF encoded by Allele 1) and the heterologous strain L2470 (expressing CBF encoded by
Allele 18 with>99% identity to the MC58 variant). However, no killing was observed with the
heterologous strains expressing CBF encoded by Allele 3. Nevertheless, and assuming that all
strains were killed in the same manner, by simple extrapolation, a single protein could poten-
tially cover worldwide at least ~84% of the total meningococcal strains in the pubmlst.org/Neis-
seria database. Notably, proteins encoded by Allele 1 can be found in all the major serogroups
(A, B, C, Y and W) causing disease. Furthermore, at least 88% of all MenB strains worldwide in
the database would be covered by immunization with a single protein capable of inducing
cross-strain bactericidal activity (S1 Table). An analysis of disease occurring specifically in the
UK, demonstrated that at least 90% of MenB isolates (n = 712/794) causing disease in recent
years (2013–2015) would be covered by using a cross-protective rCBF protein encoded by
Allele 1 and coverage could extend potentially to disease caused by the majority of MenC,
MenW and MenY isolates recorded (n = 643 isolates, S2 Table).
From this preliminary screen with a limited number of strains, we extended our study to
examine whether the anti-rCBF sera were bactericidal in the more stringent hSBA assay. How-
ever, this assay highlighted variability between strains in their ability to be killed by anti-rCBF
sera, which we have observed in a previous study with another candidate vaccine protein,
rNMB1612 [32]. We observed no killing of MC58 or MC54 MenB strains expressing protein
encoded by Allele 1 in the hSBA assay: by contrast, two other MenB strains, MC168 and
MC90, expressing the same Allele 1 protein, were killed by rCBF antibodies using HC. The lack
of killing of MC58 and MC54 was not due to differences in CBF production as judged by west-
ern blot reactivity and explanations for variability between strains in susceptibility to killing are
afforded by our rNMB1612 study. Furthermore, variability could also be linked to surface-
exposure of CBF [32]: to test this hypothesis, we used the rabbit anti-rCBF serum (with high
titre reactivity with OM and meningococcal cells and cross-reactivity with CBF proteins
encoded by different alleles) to examine by FACS the surface-exposure of CBF in the different
meningococcal strains. We observed that antibodies were capable of binding to the surface of
MC58 meningococci as well as to strains MC168, MC90 and L2470 (S4 Fig), but not to strains
MC54, M15 240010, M15 240190, M15 240016, MC162, MENC11, M15 240120 and M15
240106. Interestingly, bactericidal activity of murine antisera, whether with the BRC SBA or
the hSBA was observed against the strains showing positive FACS reactivity for CBF expres-
sion, but was absent against the strains showing no significant FACS reactivity. Thus, it is pos-
sible that variable CBF transport and surface-exposure and structural differences in OM
between strains could influence the binding of rCBF-induced antibodies to CBF bactericidal
epitopes. Furthermore, structural differences that may influence the ability of antisera to kill
meningococci with HC in particular, could include variable/different expression of capsule or
fHbp protein, which prevents complement-mediated death, and perhaps the presence of trun-
cated, non-sialylated lipooligosaccharide.
It is interesting to note that the anti-rCBF sera weakly killed a MenW strain (titre of 8) but
not a MenY strain, each encoding the homologous CBF protein (Allele 1). With respect to het-
erologous SBA, anti-rCBF sera killed only one of two strains expressing CBF encoded by Allele
18 in the hSBA assay and did not kill either of two strains that expressed CBF encoded by Allele
2. Thus, extrapolation of these data to determine coverage rates worldwide and in the UK spe-
cifically can only be hypothetical: it is unclear whether lack of killing of different strains in vitro
would be observed in humans, reflecting differences possibly in virulence, and emphasizes the
need for testing bactericidal activity with the hSBA against much larger numbers of isolates
expressing proteins encoded by the different Alleles. Thus, estimates of potential coverage of
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MenB using a rCBF protein encoded by Alelle 1 that cross-protects against strains expressing
protein encoded by Allele 18, would be significantly down-graded if only 50% of strains circu-
lating in the population behaved in the hSBA assay similarly as strain MC168, MC90 and
L2470. A similar down-grading would be observed for MenY and MenW isolates expressing
CBF encoded by Allele 1.
Conclusion
CBF protein is produced with limited variation in meningococci and rCBF protein can
induce cross-strain bactericidal antibodies. However, there appear to be differences in sur-
face-exposure of the antigen between meningococcal strains. Further studies would be
required to identify suitable, human-compatible adjuvants for use with this protein. Most
importantly, candidature for inclusion of rCBF in next-generation MenB or ‘universal’ vac-
cines will depend on demonstration of an ability to elicit bactericidal antibodies against a
much larger set of strains representative of meningococcal strain diversity associated with
meningococcal infections.
Supporting Information
S1 Fig. Western blot reactivity of murine antisera raised against MC58 outer membranes
adsorbed to Al(OH)3. Strip blots containing 5μg of protein were each reacted with pooled
murine antiserum (1/200 dilution). Wt denotes wild-type MC58 (CBF+) and Δ denotes the
MC58 Δnmb0345 (CBF- knock-out) preparation tested.
(PPTX)
S2 Fig. Alignment of non-redundant NMB0345 (NEIS1825) amino acid sequences for Neis-
seria meningitidis isolates in the http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_
neisseria_isolates database and the additional 13 strains in our collection. Database was
accessed 01-03-2016. Amino acid sequence alignments were generated using Clustal (http://
www.ebi.ac.uk/Tools/msa/clustalo/) and a dendrogram was then assembled using the non-
redundant sequences with Jalview 2.8 (www.jalview.org). Denotes identical amino acids;—
denote position of amino acid change. A denotes Allele.
(DOCX)
S3 Fig. A dendrogram showing the relationships between the 49 non-redundant NMB0345
(NEIS1825) alleles in Neisseria meningitidis isolates in the pubmlst.org/Neisseria database.
The numbers denote the average distance using % identity tree calculated by Jalview. A denotes
Allele.
(PPTX)
S4 Fig. FACS reactivity of rabbit pre-immune and anti-rCBF serum with meningococcal
strains. Pre-immune (red line) and post-immune (blue line) serum raised to rCBF in Freund’s
adjuvants was tested (1/100 dilution) in FACS against Neisseria meningitidis strains used for
serum bactericidal assays. Significant (p<0.05) right-sided shifts in FITC-recorded events was
shown for strains MC168, MC90 and L2470, whereas no significant right-sided shifts were
observed for strains MC54, M15 240010, M15 240190, M15 240016, MC162, MENC11, M15
240120 and M15 240106 (plots not shown). Positive reactivity for MC58 is shown in Fig 4B.
(PPTX)
S1 Table. Analysis of NMB0345 (NEIS1825) alleles and number of isolates per serogroup:
data are collated from http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_neisseria_
isolates and also include the 13 strains from our collection. Numbers in parentheses indicate
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that the Alleles produce proteins with identical amino acid sequences. Database was accessed
01-03-2106 and there are 136 allelic loci with isolates generating 49 non-redundant protein
amino acid sequences. NG, no serogroup identified; ND, not determined. Table sorted numeri-
cally according to Alleles containing similar allelic proteins and then single Alleles.
(DOCX)
S2 Table. Analysis of NMB0345 (NEIS1825) alleles and number of isolates per serogroup
for UK data 2013–2015: data are collated from http://pubmlst.org/perl/bigsdb/bigsdb.pl?
db=pubmlst_neisseria_isolates.Numbers in parentheses indicate that the Alleles produce
proteins with identical amino acid sequences. Database was accessed 01-03-2016 for the UK
from 2013–2015, the most recent data. NG, no serogroup identified; ND, not determined.
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